公开(公告)号：US20160184362A1

公开(公告)日：2016-06-30

申请号：US15045368

申请日：2016-02-17

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: A61K35/17 ,  C12N9/22 ,  C12N15/90 ,  A61K47/48 ,  C12N5/0783

CPC classification number: C12N15/85 ,  A61K35/17 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N9/22 ,  C12N15/1138 ,  C12N15/90 ,  C12N2310/20 ,  C12N2510/00 ,  C12Y301/00

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20230279350A1

公开(公告)日：2023-09-07

申请号：US18016972

申请日：2021-07-30

Applicant: CELLECTIS S.A.

Inventor： André CHOULIKA ,  Laurent POIROT ,  Beatriz ARANDA ORGILLES ,  Philippe DUCHATEAU

IPC: C12N5/0783 ,  C07K16/28 ,  A61P35/00

CPC classification number: C12N5/0636 ,  C07K16/2887 ,  C07K16/2896 ,  A61P35/00 ,  C07K2317/53 ,  C07K2317/565 ,  C07K2319/03

Abstract: The present invention concerns new engineered immune cells expressing two CARs directed against two different targets, polynucleotides for preparing said immune cells, pharmaceutical compositions comprising said immune cells, and the use of said immune cells in the treatment of cancers.

公开(公告)号：US20210147868A1

公开(公告)日：2021-05-20

申请号：US16953473

申请日：2020-11-20

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  A61K35/17 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20200181643A1

公开(公告)日：2020-06-11

申请号：US16793918

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  C12N5/0783 ,  C12N15/90 ,  C12N9/22 ,  A61K35/17

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20200277625A1

公开(公告)日：2020-09-03

申请号：US16793896

申请日：2020-02-18

Applicant: Cellectis

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85 ,  A61K35/17 ,  C12N5/0783 ,  C12N9/22 ,  C12N15/90

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

公开(公告)号：US20160272999A1

公开(公告)日：2016-09-22

申请号：US14892934

申请日：2014-04-01

Applicant: CELLECTIS

Inventor： Philippe DUCHATEAU ,  André CHOULIKA ,  Laurent POIROT

IPC: C12N15/85

CPC classification number: C12N15/85 ,  C12N5/0636 ,  C12N5/0637 ,  C12N5/0638 ,  C12N9/22 ,  C12N2510/00

Abstract: The present invention relates to methods of developing genetically engineered, preferably non-alloreactive T-cells for immunotherapy. This method involves the use of RNA-guided endonucleases, in particular Cas9/CRISPR system, to specifically target a selection of key genes in T-cells. The engineered T-cells are also intended to express chimeric antigen receptors (CAR) to redirect their immune activity towards malignant or infected cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies using T-Cells for treating cancer and viral infections.

Abstract translation: 本发明涉及开发用于免疫治疗的遗传工程化，优选非同种异体反应性T细胞的方法。 该方法涉及使用RNA引导的核酸内切酶，特别是Cas9 / CRISPR系统，以特异性靶向T细胞中关键基因的选择。 工程化T细胞还旨在表达嵌合抗原受体（CAR）以将其免疫活性重定向于恶性或感染细胞。 本发明开启了使用T细胞治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。